Annual SGA
$50.18 M
+$18.43 M+58.05%
December 31, 2024
Summary
- As of March 10, 2025, AQST annual SGA is $50.18 million, with the most recent change of +$18.43 million (+58.05%) on December 31, 2024.
- During the last 3 years, AQST annual SGA has fallen by -$3.29 million (-6.16%).
- AQST annual SGA is now -30.56% below its all-time high of $72.27 million, reached on December 31, 2018.
Performance
AQST SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$16.01 M
+$3.88 M+32.02%
December 31, 2024
Summary
- As of March 10, 2025, AQST quarterly SGA is $16.01 million, with the most recent change of +$3.88 million (+32.02%) on December 31, 2024.
- Over the past year, AQST quarterly SGA has stayed the same.
- AQST quarterly SGA is now -52.45% below its all-time high of $33.67 million, reached on June 30, 2018.
Performance
AQST Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.38 B
-$44.14 M-3.31%
December 31, 2024
Summary
- As of March 10, 2025, AQST TTM SGA is -$1.38 billion, with the most recent change of -$44.14 million (-3.31%) on December 31, 2024.
- Over the past year, AQST TTM SGA has dropped by -$1.43 billion (-2841.98%).
- AQST TTM SGA is now -1045.72% below its all-time high of -$120.09 million.
Performance
AQST TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
AQST Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +58.0% | 0.0% | -2842.0% |
| 3 y3 years | -6.2% | +116.8% | -4145.4% |
| 5 y5 years | -22.0% | +116.8% | -4145.4% |
AQST Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -6.2% | +58.0% | at high | +117.5% | -53.1% | at low |
| 5 y | 5-year | -22.0% | +58.0% | -2.8% | +117.5% | -222.5% | at low |
| alltime | all time | -30.6% | +141.2% | -52.5% | +206.5% | -1045.7% | at low |
Aquestive Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $50.18 M(+58.0%) | $16.01 M(+32.0%) | $50.18 M(+14.8%) |
| Sep 2024 | - | $12.13 M(+6.8%) | $43.72 M(+12.2%) |
| Jun 2024 | - | $11.36 M(+6.2%) | $38.98 M(+11.4%) |
| Mar 2024 | - | $10.69 M(+11.9%) | $34.98 M(+10.2%) |
| Dec 2023 | $31.75 M(-40.0%) | $9.55 M(+29.3%) | $31.75 M(-6.7%) |
| Sep 2023 | - | $7.38 M(+0.3%) | $34.01 M(-13.0%) |
| Jun 2023 | - | $7.36 M(-1.3%) | $39.09 M(-17.4%) |
| Mar 2023 | - | $7.46 M(-36.9%) | $47.31 M(-10.5%) |
| Dec 2022 | $52.88 M(-1.1%) | $11.81 M(-5.2%) | $52.88 M(-5.7%) |
| Sep 2022 | - | $12.46 M(-20.1%) | $56.05 M(+0.6%) |
| Jun 2022 | - | $15.59 M(+19.7%) | $55.72 M(+4.6%) |
| Mar 2022 | - | $13.02 M(-13.1%) | $53.27 M(-0.4%) |
| Dec 2021 | $53.48 M(-4.3%) | $14.98 M(+23.5%) | $53.48 M(-1.1%) |
| Sep 2021 | - | $12.13 M(-7.7%) | $54.08 M(+0.6%) |
| Jun 2021 | - | $13.13 M(-0.7%) | $53.75 M(-1.4%) |
| Mar 2021 | - | $13.23 M(-15.1%) | $54.51 M(-2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $55.89 M(-13.1%) | $15.58 M(+32.0%) | $55.89 M(-1.6%) |
| Sep 2020 | - | $11.80 M(-15.0%) | $56.78 M(-3.3%) |
| Jun 2020 | - | $13.89 M(-4.9%) | $58.70 M(-3.9%) |
| Mar 2020 | - | $14.61 M(-11.3%) | $61.05 M(-5.1%) |
| Dec 2019 | $64.34 M(-11.0%) | $16.47 M(+20.1%) | $64.34 M(-3.4%) |
| Sep 2019 | - | $13.71 M(-15.6%) | $66.58 M(+2.1%) |
| Jun 2019 | - | $16.25 M(-9.3%) | $65.21 M(-21.1%) |
| Mar 2019 | - | $17.91 M(-4.3%) | $82.63 M(+14.3%) |
| Dec 2018 | $72.27 M(+188.2%) | $18.71 M(+51.5%) | $72.29 M(+18.2%) |
| Sep 2018 | - | $12.35 M(-63.3%) | $61.15 M(+11.3%) |
| Jun 2018 | - | $33.67 M(+344.8%) | $54.96 M(+107.3%) |
| Mar 2018 | - | $7.57 M(+0.1%) | $26.52 M(+5.7%) |
| Dec 2017 | $25.08 M(+20.5%) | $7.57 M(+22.8%) | $25.08 M(+43.2%) |
| Sep 2017 | - | $6.16 M(+18.0%) | $17.51 M(+54.3%) |
| Jun 2017 | - | $5.22 M(-14.8%) | $11.35 M(+85.2%) |
| Mar 2017 | - | $6.13 M | $6.13 M |
| Dec 2016 | $20.80 M | - | - |
FAQ
- What is Aquestive Therapeutics annual SGA?
- What is the all time high annual SGA for Aquestive Therapeutics?
- What is Aquestive Therapeutics annual SGA year-on-year change?
- What is Aquestive Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Aquestive Therapeutics?
- What is Aquestive Therapeutics quarterly SGA year-on-year change?
- What is Aquestive Therapeutics TTM SGA?
- What is the all time high TTM SGA for Aquestive Therapeutics?
- What is Aquestive Therapeutics TTM SGA year-on-year change?
What is Aquestive Therapeutics annual SGA?
The current annual SGA of AQST is $50.18 M
What is the all time high annual SGA for Aquestive Therapeutics?
Aquestive Therapeutics all-time high annual SGA is $72.27 M
What is Aquestive Therapeutics annual SGA year-on-year change?
Over the past year, AQST annual SGA has changed by +$18.43 M (+58.05%)
What is Aquestive Therapeutics quarterly SGA?
The current quarterly SGA of AQST is $16.01 M
What is the all time high quarterly SGA for Aquestive Therapeutics?
Aquestive Therapeutics all-time high quarterly SGA is $33.67 M
What is Aquestive Therapeutics quarterly SGA year-on-year change?
Over the past year, AQST quarterly SGA has changed by $0.00 (0.00%)
What is Aquestive Therapeutics TTM SGA?
The current TTM SGA of AQST is -$1.38 B
What is the all time high TTM SGA for Aquestive Therapeutics?
Aquestive Therapeutics all-time high TTM SGA is -$120.09 M
What is Aquestive Therapeutics TTM SGA year-on-year change?
Over the past year, AQST TTM SGA has changed by -$1.43 B (-2841.98%)